IMMUN TIZIM VA KO‘KRAK BEZI SARATONI O‘RTASIDAGI BOG‘LIQLIK
Keywords:
immun tizim, ko‘krak bezi saratoni, immun javob, T-limfotsitlar, sitokinlarAbstract
Ko‘krak bezi saratoni rivojlanishida immun tizimning holati muhim biologik omillardan biri hisoblanadi. Inson organizmining immun tizimi o‘smaga qarshi tabiiy himoya mexanizmini ta’minlab, atipik hujayralarni aniqlash va yo‘q qilishda asosiy rol o‘ynaydi. Biroq immun nazorat mexanizmlarining susayishi yoki o‘sma hujayralarining immun javobdan qochish qobiliyati saraton rivojlanishi va metastaz jarayonini tezlashtirishi mumkin. Mazkur tadqiqotda immun tizim komponentlari — T-limfotsitlar, B-limfotsitlar, tabiiy killer hujayralar hamda sitokinlarning ko‘krak bezi saratoni patogenezidagi o‘rni ilmiy manbalar asosida tahlil qilinadi. Shuningdek, o‘sma mikro-muhiti va immun yallig‘lanish jarayonlari o‘rtasidagi o‘zaro ta’sir mexanizmlari yoritiladi. Zamonaviy immunoterapiya usullarining qo‘llanilishi saraton hujayralariga qarshi immun javobni kuchaytirish orqali davolash samaradorligini oshirish imkonini berishi aniqlangan. Tadqiqot natijalari immun tizim holatini baholash ko‘krak bezi saratonini erta prognoz qilish, individual davolash strategiyasini tanlash hamda kasallikning qaytalanish xavfini kamaytirishda muhim ahamiyatga ega ekanligini ko‘rsatadi.
References
1. Adams, S., Schmid, P., Rugo, H. S., et al. (2019). Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: KEYNOTE-086 study results. Journal of Clinical Oncology, 37(14), 1219–1228.
2. Denkert, C., von Minckwitz, G., Brase, J. C., et al. (2010). Tumor-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: A pooled analysis. Journal of Clinical Oncology, 28(1), 105–115.
3. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646–674.
4. Loi, S., Sirtaine, N., Piette, F., et al. (2013). Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial. Journal of Clinical Oncology, 31(7), 860–867.
5. Mittendorf, E. A., Philips, A. V., Meric-Bernstam, F., et al. (2014). PD-L1 expression in triple-negative breast cancer. Cancer Immunology Research, 2(4), 361–370.
6. Schmid, P., Adams, S., Rugo, H. S., et al. (2018). Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. New England Journal of Medicine, 379, 2108–2121.
7. Emens, L. A. (2018). Breast cancer immunotherapy: facts and hopes. Clinical Cancer Research, 24(3), 511–520.
8. Salgado, R., Denkert, C., Demaria, S., et al. (2015). The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group 2014. Annals of Oncology, 26(2), 259–271.
9. Mittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014). New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape. Current Opinion in Immunology, 27, 16–25.
